At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ELVN Enliven Treateutics
Trading 03-28 13:20:50 EDT
21.18
-0.33
-1.56%
| High22.12 | Low20.97 | Vol67.36K |
| Open21.57 | D1 Closing21.51 | Amplitude5.37% |
| Mkt Cap1.04B | Tradable Cap570.19M | Total Shares49.00M |
| T/O1.45M | T/O Rate0.25% | Tradable Shares26.93M |
| P/B3.35 | ROE-32.04% | EPS-1.89 |
| 52wk High30.03 | 52wk Low15.96 | P/E-11.20 |
| Dividend0.00 | Div.Yield0.00 | ROA-21.87% |
Enliven Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03-21
Enliven Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $39 From $37
THOMSON REUTERS · 03-21
Enliven Therapeutics Q4 Operating Expenses USD 26.896 Million
Reuters · 03-13
Enliven Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 03-13
Strong Buy Recommendation for Enliven Therapeutics Due to ELVN-001’s High Selectivity and Promising Clinical Data
TIPRANKS · 02-04
Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans
Simply Wall St. · 2024-12-14
Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans
Enliven Therapeutics Inc : Btig Initiates Coverage With Buy Rating; Price Target $42
THOMSON REUTERS · 2024-12-13
Enliven Therapeutics’ ELVN-001: Navigating Competitive Challenges and Opportunities in the CML Market
TIPRANKS · 2024-12-10
Promising Market Potential for Enliven Therapeutics’ ELVN-001 in Post-Asciminib CML Treatment Landscape
TIPRANKS · 2024-12-09
Enliven price target raised to $40 from $32 at Baird
TIPRANKS · 2024-11-15
Enliven Therapeutics Inc : Jefferies Raises Target Price to $33 From $32
THOMSON REUTERS · 2024-11-14
Enliven Therapeutics Inc: Current Cash, Cash Equivalents and Marketable Securities Expected to Provide Cash Runway Into Late 2026
THOMSON REUTERS · 2024-11-13
Enliven Therapeutics Q3 Operating Expenses USD 27.068 Million
THOMSON REUTERS · 2024-11-13
Press Release: Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Dow Jones · 2024-11-13
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference
PR Newswire · 2024-11-07
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference
JonesTrading Initiates Enliven Therapeutics at Buy With $36 Price Target
MT Newswires Live · 2024-10-31
Enliven initiated with a Buy at JonesResearch
TIPRANKS · 2024-10-30
TD Cowen Sticks to Their Buy Rating for Enliven Therapeutics (ELVN)
TIPRANKS · 2024-09-30
Analysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Enliven Therapeutics (ELVN)
TIPRANKS · 2024-09-30
BRIEF-Enliven Therapeutics Announces Positive Data Update From Phase 1 Clinical Trial Of ELVN-001 In Chronic Myeloid Leukemia
Reuters · 2024-09-28
Introduction
Company Name.
Enliven Treateutics
Affiliated Markets:
NASDAQ
Listing Date:
2020-03-12
Main Business:
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Issue price:
16.00
Invest in Global Markets with Tiger Brokers!Open App